Over recent years, there has been a notable increase in the number of orphan drugs being successfully brought to market. Here, Jennifer Peters of Greenphire speaks to International Pharmaceutical Industry about the orphan drugs market, the unique logistical challenges faced by organisations when conducting clinical trials for this type of drug, and how addressing payment processes and financial management strategies can overcome them.